Zogenix, Inc. (OQ:ZGNX)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 5959 Horton St Ste 500
EMERYVILLE CA 94608-2120
Tel: N/A
Website: www.zogenix.com
IR: See website
<
Key People
Cam L. Garner
Independent Chairman of the Board
Stephen J. Farr
President, Chief Executive Officer, Director
Michael P. Smith
Chief Financial Officer, Executive Vice President, Treasurer
Shawnte M. Mitchell
Executive Vice President, General Counsel, Secretary
Gail M. Farfel
Executive Vice President, Chief Development Officer
Bradley S. Galer
Executive Vice President, Chief Medical Officer
Ashish M. Sagrolikar
Executive Vice President, Chief Commercial Officer
   
Business Overview
Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.
Financial Overview
For the three months ended 31 March 2020, Zogenix, Inc. revenues increased from $0K to $1.2M. Net loss decreased 27% to $25.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other income (expense) increase from $88K (expense) to $20M (income), Fair Value Adjustments on Other Assets decrease from $3M (expense) to $7.9M (income).
Employees: 141 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $1,189M as of Mar 31, 2020
Annual revenue (TTM): $4.90M as of Mar 31, 2020
EBITDA (TTM): -$184.09M as of Mar 31, 2020
Net annual income (TTM): -$410.10M as of Mar 31, 2020
Free cash flow (TTM): -$145.83M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 55,340,691 as of Apr 9, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization